

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

RANBAXY INC.  
Petitioner,

v.

JAZZ PHARMACEUTICALS, INC. and  
JAZZ PHARMACEUTICALS IRELAND LTD.  
Patent Owner

---

Case IPR2016-00738  
Patent 9,050,302

---

**PATENT OWNER MANDATORY NOTICES UNDER  
35 U.S.C. §§ 311-319 AND 37 C.F.R. §§ 42.8, 42.100 ET. SEQ.**

**REAL PARTIES-IN-INTEREST**

Pursuant to the requirements of 37 C.F.R. § 42.8(b)(1), the undersigned state that Jazz Pharmaceuticals, Inc. (“Jazz”) and Jazz Pharmaceuticals Ireland Ltd. (“Jazz Ireland”) are the real parties-in-interest. Jazz is a corporation organized and existing under the laws of the State of Delaware, having a principal place of business at 3180 Porter Drive, Palo Alto, California 94304. Jazz Ireland is a corporation existing under the laws of Ireland, having a principle place of business at One Burlington Road, Fourth Floor, Connaught House, Dublin, Ireland 4. Jazz Ireland owns by assignment the entire right, title, and interest in U.S. Patent No. 9,050,302 (the “’302 patent”) by virtue of an Assignment of rights from the inventor, Mark Eller, to Jazz (Reel/Frame 30652-164), and Assignment of rights from Jazz to Jazz Ireland (Reel/Frame 33480-135). The Assignments were recorded with the United States Patent and Trademark Office on May 24, 2013 and July 29, 2014. Jazz is currently the exclusive licensee of the ’302 patent.

**RELATED MATTERS**

Pursuant to 37 C.F.R. § 42.8(b)(2), the undersigned state that the ’302 patent is the subject of six, currently-pending litigations: *Jazz Pharmaceuticals, Inc. et al. v. Amneal Pharmaceuticals, LLC, et al.*, 2:13-cv-391 (D.N.J.) (consolidated); *Jazz Pharmaceuticals, Inc., et al. v. Roxane Laboratories, Inc.*, 2:15-cv-1360 (D.N.J.)

(consolidated); *Jazz Pharmaceuticals, Inc. et al. v. Watson Laboratories, Inc.*, 2:16-cv-1505 (D.N.J.); *Jazz Pharmaceuticals, Inc. et al. v. Wockhardt Bio AG et al.*, 2:16-cv-99 (D.N.J.); *Jazz Pharmaceuticals, Inc. et al. v. Sun Pharmaceutical Industries Ltd., et al.*, 2:15-cv-8229 (D.N.J.); *Jazz Pharmaceuticals, Inc. et al. v. Par Pharmaceutical, Inc.*, 2:15-cv-7580 (D.N.J.); and *Jazz Pharmaceuticals, Inc. et al. v. Amneal Pharmaceuticals, LLC*, 2:15-cv-6562 (D.N.J.).

Three other *inter partes* reviews filed by Par Pharmaceutical, Inc. (IPR2016-00002), Ranbaxy Inc. (IPR2016-00024) and Amneal Pharmaceuticals LLC (IPR2016-00546), concern a patent related to the '302 patent.

Further, PCT/US14/19217, filed on February 28, 2014, and U.S. Application No. 14/707,914, filed on May 8, 2015, claim the benefit of the '302 patent.

**LEAD COUNSEL AND BACK-UP COUNSEL (37 C.F.R. § 42.8(b)(3))**

Lead Counsel: F. Dominic Cerrito (Reg. No. 38,100)

Contact Information: Quinn Emanuel Urquhart & Sullivan, LLP  
51 Madison Avenue, 22<sup>nd</sup> Floor  
New York, NY 10010  
Email: [nickcerrito@quinnemanuel.com](mailto:nickcerrito@quinnemanuel.com)  
Telephone: 212-849-7000

Back-Up Counsel: Evangeline Shih (Reg. No. 50,170)

Contact Information: Quinn Emanuel Urquhart & Sullivan, LLP  
51 Madison Avenue, 22<sup>nd</sup> Floor  
New York, NY 10010  
Email: [evangelineshih@quinnemanuel.com](mailto:evangelineshih@quinnemanuel.com)  
Telephone: 212-849-7000

Back-Up Counsel: Frank C. Calvosa (Reg. No. 69,064)

Contact Information: Quinn Emanuel Urquhart & Sullivan, LLP  
51 Madison Avenue, 22<sup>nd</sup> Floor  
New York, NY 10010  
Email: [frankcalvosa@quinnemanuel.com](mailto:frankcalvosa@quinnemanuel.com)  
Telephone: 212-849-7000

Back-Up Counsel: Michael Tuscan (Reg. No. 40,210)

Contact Information: Cooley LLP  
1299 Pennsylvania Avenue, NW  
Suite 700  
Washington, DC 20004  
Email: [mtuscan@cooley.com](mailto:mtuscan@cooley.com)  
Telephone: 202-842-7802

Back-Up Counsel: Thomas Blinka (Reg. No. 44,541)

Contact Information: Cooley LLP

1299 Pennsylvania Avenue, NW

Suite 700

Washington, DC 20004

Email: tblinka@cooley.com

Telephone: 202-842-7865

**SERVICE INFORMATION**

Pursuant to 37 C.F.R. § 42.8(b)(4), please direct all correspondence to lead and back-up counsel at the above addresses. Patent Owner consents to email service at the above-specified email addresses.

Date: March 31, 2016

Respectfully submitted,

By: /F. Dominic Cerrito (Reg. No. 38,100)/

F. Dominic Cerrito (Reg. No. 38,100)

Evangeline Shih (Reg. No. 50,170)

Frank C. Calvosa (Reg. No. 69,064)

QUINN EMANUEL URQUHART &

SULLIVAN LLP

51 Madison Avenue, 22<sup>nd</sup> Floor

New York, NY 10010

Tel: (212) 849-7000

Fax: (212) 849-7100

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.